2Segev A, Nili N, Strauss BH. The role of perlecan in arterial injury and angiogenesis. Cardiovasc Res, 2004, 63 : 603-610.
3Onimaru M, Yonemitsu Y, Tanii M, et al. Fibroblast growth factor-2 gene transfer canstimulate hepaocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limb. Circ Res, 2002, 91 : 923 -930.
4Walker HA, Whitelock JM, Garl PJ,et al. Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol Biol Cell, 2003, 14 :1941 - 1952.
5Kinsella MG, Tran PK, Weiser-Evans MC, et al. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Artefioscler Thromb Vasc Biol, 2003, 23 : 608 -614.
7Mongiat M, Fu J, Oldershaw R,et al. Perlecan protein core interacts with extracellular matrix protein 1 ( ECM1 ), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem, 2003, 278 : 17491 - 17499.
8Knox S, Merry C, Stringer S, Melrose J, et al. Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. J Biol Chem, 2002,277 : 14657- 14665.
9Xu Y, Liu YJ, Yu Q. Angiopoletin-3 is tethered on the cell surface via heparan sulfate proteoglycans. J Biol Chem.2004,279 : 41179 -41188.
10Zhang W, Chuang YJ, Swanson R, et al. Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood, 2004, 103 : 1185 - 1191.
二级参考文献10
1[1]Costell M, Gustafsson E, Aszodi A, et al. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol,1999,147:1109～1122.
2[2]Costell M,Carmona R,Gustafsson E,et al.Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice.Circ Res,2002,91:158～164.
3[3]Arikawa-Hirasawa E, Le AH, Nishino I, et al. Structural and functional mutations of the perlecan gene cause Schwartz-Jampelsyndrome, with myotonic myopathy and chondrodysplasia. Am J Hum Genet,2002,70:1368～1375.
4[4]Belknap JK, Weiser-Evans MC, Grieshaber SS, et al. Relationship between perlecan and tropoelastin gene expression and cell replication in the developing rat pulmonary vasculature.Am J Respir Cell Mol Biol,1999,20:24～34.
5[5]Whitelock JM, Graham LD, Melrose J, et al. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol, 1999, 18:163～178.
6[6]Pillarisetti S. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med, 2000, 10:60～65.
7[7]Evanko SP, Raines EW, Ross R, et al. Proteoglycan distribution in lesions of atherosclerosis depends on lesionseverity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol, 1998, 152:533～546.
8[8]Nugent MA,Nugent HM,Iozzo RV,et al.Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia.Proc Natl Acad Sci USA,2000, 97:6722～6727 .
9[9]Chung IM,Gold HK,Schwartz SM,et al.Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment.J Am Coll Cardiol,2002, 40:2072～2081.
10[10]Nakahama M,Murakami T,Kusachi S,et al.Expression of perlecan proteoglycan in the infarct zone of mouse myocardial infarction.J Mol Cell Cardiol,2000,32:1087～1100.
